检验医学 ›› 2026, Vol. 41 ›› Issue (6): 597-602.DOI: 10.3969/j.issn.1673-8640.2026.06.012

• 论著 • 上一篇    下一篇

血浆AT可用于评估多发性骨髓瘤患者肾损伤及其预后

孙常铭1, 王丽萍2, 赵维川1(), 朴宗方1, 郭轶群1   

  1. 1 承德医学院附属医院检验科河北 承德 067000
    2 承德医学院附属医院输血科河北 承德 067000
  • 收稿日期:2024-06-05 修回日期:2025-08-14 出版日期:2026-06-30 发布日期:2026-07-01
  • 通讯作者: 赵维川,E-mail:15633142985@163.com
  • 作者简介:孙常铭,男,1982年生,硕士,副主任技师,主要从事临床血液学检验工作。
  • 基金资助:
    2021年承德市科学技术研究与发展计划项目(202109A188)

Application of plasma AT in renal injury and prognosis evaluation of multiple myeloma patients

SUN Changming1, WANG Liping2, ZHAO Weichuan1(), PIAO Zongfang1, GUO Yiqun1   

  1. 1 Department of Clinical Laboratorythe Affiliated Hospital of Chengde Medical College,Chengde 067000Hebei, China
    2 Department of Blood Transfusionthe Affiliated Hospital of Chengde Medical College,Chengde 067000Hebei, China
  • Received:2024-06-05 Revised:2025-08-14 Online:2026-06-30 Published:2026-07-01

摘要:

目的 分析血浆抗凝血酶(AT)活性在多发性骨髓瘤(MM)患者肾损伤中的临床意义。方法 收集2018年1月—2020年10月承德医学院附属医院60例初诊MM患者(MM组)和60例初诊肾病患者(对照组)。比较不同免疫类型MM患者AT活性差异。根据肌酐水平,将MM组和对照组分别细分为肾功能正常组、肾功能受损组和肾功能正常对照组、肾功能受损对照组。采用Person相关分析评估MM患者AT活性和胱抑素C(Cys C)的相关性。采用受试者工作特征(ROC)曲线评估AT和Cys C诊断MM患者肾损伤的效能。对MM患者进行随访,比较不同AT活性和Cys C水平患者化疗后生存时间差异。结果 不同免疫类型MM患者AT活性差异有统计学意义(F=13.144,P<0.05);轻链型、IgG型、lgA型、不分泌型MM患者AT活性依次升高。肾功能正常MM患者血浆AT活性高于肾功能异常MM患者,肾功能正常对照组血浆AT活性高于肾功能受损对照组(P<0.05),肾功能受损组血浆AT活性高于肾功能受损对照组(P<0.05)。肾损伤MM患者AT活性和Cys C呈负相关(r=-0.554,P=0.004)。AT和Cys C诊断MM患者肾损伤的曲线下面积(AUC)分别为0.887和0.625。AT活性正常MM患者治疗后生存时间长于AT活性下降MM患者(P<0.05);AT活性正常Cys C正常MM患者化疗后生存时间长于AT活性下降Cys C升高和AT活性正常Cys C升高MM患者(P<0.05)。结论 MM患者血浆AT活性与患者的免疫类型有关;AT活性可用于评估MM患者肾损伤。

关键词: 抗凝血酶, 多发性骨髓瘤, 肾损伤, 肌酐, 胱抑素C

Abstract:

Objective To analyze the clinical role of plasma antithrombin(AT) activities in patients with multiple myeloma(MM) with renal injury. Methods The data of 60 newly diagnosed MM patients(MM group) and 60 newly diagnosed patients with kidney disease(control group) from the Affiliated Hospital of Chengde Medical College from January 2018 to October 2020 were collected. The differences in AT activity among different immunological types of MM patients were compared. According to serum creatinine(SCr) level,the MM group and the control group were further classified into normal renal function,impaired renal function,normal renal function control group and impaired renal function control group. Pearson correlation analysis was used to evaluate the correlation between AT activity and cystatin C(Cys C) in MM patients. Receiver operating characteristic(ROC) curve was used to evaluate the efficacy of AT and Cys C in diagnosing renal injury in MM patients. Follow-up was conducted for MM patients,and the differences in survival time after chemotherapy among patients with different AT activities and Cys C levels were compared. Results There was statistical significance in AT activity among patients with different immune types of MM(F=13.144,P<0.05). The AT activity increased in the order of light chain type,IgG type,IgA type and non-secretory type MM patients. The plasma AT activity of MM patients with normal renal function was better than that of MM patients with impaired renal function(P<0.05),and the plasma AT activity of impaired renal function control group was lower than that of normal renal function control group(P<0.05). The plasma AT activity in impaired renal function group was higher than that in impaired renal function control group(P<0.05). The AT activity and Cys C of MM patients with renal injury were negatively correlated(r=-0.554,P=0.004). The areas under curves(AUC) of AT activity and Cys C for diagnosing renal injury in MM patients were 0.887 and 0.625,respectively. The survival time after treatment was longer in MM patients with normal AT activity and normal Cys C than in MM patients with reduced AT activity and increased Cys C,and also longer than in MM patients with normal AT activity and increased Cys C(P<0.05). Conclusions The plasma AT activity in MM patients is related to the immunological type of the patients. The AT activity can be used to assess renal injury in MM patients.

Key words: Antithrombin, Multiple myeloma, Renal injury, Creatinine, Cystatin C

中图分类号: